Clinical trial · Interventional
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (11)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Best Supportive Care | Other | — | UNRESOLVED |
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Crizotinib | Drug | Crizotinib | ALIAS |
| Docetaxel | Drug | Docetaxel | ALIAS |
| Erlotinib | Drug | Erlotinib | ALIAS |
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| nab-Paclitaxel | Drug | Nab-paclitaxel | ALIAS |
| Nivolumab |
Design
Arms and outcomes
Arms (10)
- type
- EXPERIMENTAL
- label
- Group A Nivolumab
- description
- Opdivo specified dose on specified days
- interventionNames
- Drug: Nivolumab
- type
- EXPERIMENTAL
- label
- Group A Nivolumab + SOC maintenance therapy
- description
- Opdivo/Bevacizumab specified dose on specified days Opdivo/Pemetrexed specified dose on specified days
- interventionNames
- Drug: Nivolumab
- Drug: Bevacizumab
- Drug: Pemetrexed
- type
- ACTIVE_COMPARATOR
- label
- Group A SOC maintenance therapy
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Histologically confirmed locally advanced or stage IV NSCLC * Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2 * Tumor tissue sections must be available for biomarker evaluation Exclusion Criteria: * Untreated or active/progressing Central Nervous system (CNS) metastases * Active, known or suspected autoimmune disease * Known history of testing positive for HIV or AIDS * Active or chronic infection of hepatitis B virus or hepatitis C
References
Publications (0)
Data not yet available